Address
1 Corporate Drive
South San Francisco, CA 94080

Contact
contact@soley.ai

Cells Are Talkative. We Just Learned How To Listen.

Soley’s innovative evaluation platform decodes Cellular Language at scale for efficient drug discovery and development.

Our Interdisciplinary Approach

Soley Therapeutics is the brainchild of cardiologist Yerem Yeghiazarians, MD, and molecular cancer biologist Kurosh Ameri, PhD. They began working together in 2010 to answer the question “how do cells determine their fate?”

Why can cancer cells thrive under harsh conditions, while brain and heart muscle cells begin to die within minutes of exposure to low oxygen and nutrients?

All cells respond to their environment based on their internal flow of information. Soley’s powerful platform technology interprets this nuanced cellular response through a target-agnostic lens, highlighting potential drug candidates.

About Us
Our Science

A New Age for Life Sciences

Soley’s groundbreaking high-throughput platform technology uses the cell as a natural sensor. It harnesses cells’ anticipatory biological capabilities, and utilizes the power of AI/ML to discover and develop drugs efficiently and effectively.

Our Platform
Soley Pipeline

Dan Von Hoff, M.D.

  • 30+ years pioneer in oncology drug development
  • Distinguished Professor and Physician in Chief, Translational Genomics Research Institute
  • Professor of Medicine at University of Arizona and Mayo Clinic
  • Former National Cancer Advisory Board Member
  • Past President of the American Association for Cancer Research
  • Contributed to development of Abraxane®(nab-paclitaxel), Camptosar® irinotecan, Gemzar® gemcitabine and many other

Afsaneh Naimollah

Linkedin
  • 30+ years of experience corporate finance, strategy advisory and investment banking
  • Executive in Residence, Plug and Play Tech Center
  • Managing Partner, XEN Partners
  • Former Global Head of Barclays Capital Technology Group

Leo Grady, PhD

Linkedin
  • 20+ years of industry experience leading AI/ML, computer vision, and digital health tech
  • Founder and CEO, Stealth AI healthcare company
  • Former CEO of PaigeAI
  • Former SVP of Engineering, Heartflow
  • Founder and CEO of Jona
  • CEO in Residence at Breyer Capital

Fei-Fei Li, PhD

Linkedin
  • Sequoia Professor of Computer Science, Stanford University
  • Co-Director, Stanford Human Centered AI Institute
  • Creator of ImageNet
  • Co-Founder, Chairperson of the Board, AI4ALL
  • Former Chief Scientist of AI/ML, VP Google

Peter Libby, MD

Linkedin
  • Mallinckrodt Professor of Medicine, Cardiovascular Specialist, Harvard Medical School and Brigham and Women’s Hospital
  • World renowned expert in atherosclerosis, cardiovascular medicine and clonal hematopoiesis of indeterminate potential

Keith Flaherty, MD

  • Professor of Medicine, Harvard Medical School
  • Director of Clinical Research, Cancer Center, Massachusetts General Hospital
  • 25+ years expertise in oncology research, drug development, and targeted cancer therapies
  • Co-founder of Loxo Oncology, X4-Pharma, Strata Oncology, Apricity Oncology, Scorpion Therapeutics

Clay Johnston, MD, PhD

Linkedin
  • Professor of Neurology
  • Inaugural Dean, Dell Medical School, UT Austin
  • Former Associate Vice Chancellor of Research, UCSF
  • Co-Founder, Harbor Health

Tony Adamis, MD

  • 30+ years of industry R&D experience
  • Former SVP, Development Innovation, Genentech
  • Co-discovery of VEGF in ocular disease
  • Co-founder, Director, EyeBio

Antoine Yver, MD

Linkedin
  • 30+ years experience and world leader in oncology drug development
  • Board Member, Sanofi
  • Former Head of Oncology Global Medicine Development, AstraZeneca
  • Former Chairman of Development, Centessa
  • Former EVP, Global Head of Oncology R&D, Daiichi Sankyo
  • Contributed to development of Tagrisso® osimertinib, Lynparza® olaparib, Enhertu® trastuzumab deruxtecan and many other

Dan Von Hoff, MD

Co-Founder, CEO, Board Member

Linkedin
  • 30 years of academic experience in patient care, teaching, clinical/basic and stem cell research
  • Expertise in physiologic cellular stress, stem cells, cardiomyocytes, and neuronal cells
  • The Johns Hopkins School of Medicine (1995): M.D.
  • Harvard Medical School / Brigham and Women’s Hospital (1995-2003): internship, residency, chief residency, general and interventional cardiology
  • UCSF (since 2003): Translational Cardiac Stem Cell Program: Founder and Director